Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators), PDL1 modulators(Programmed death-ligand 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Biosion, Inc.Startup |
Active Organization Biosion, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | Biosion, Inc.Startup | 21 Mar 2024 |